Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Covance, Merck & Co. Finalize Strategic Agreement
Covance has closed its transaction with Merck to provide an array of genomics analysis services under a five-year $145m contract, and to acquire Merck’s Seattle-based Gene Expression Laboratory.
Covance has closed its transaction with Merck to provide an array of genomics analysis services under a five-year $145m contract, and to acquire Merck’s Seattle-based Gene Expression Laboratory.
Novavax has reported positive preclinical results with its 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. Under a collaborative agreement, the study has been conducted by the scientists
Basilea Pharmaceutica said that the US FDA has issed a warning letter to Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) related to ceftobiprole clinical trials, for the
IsoRay has received clearance from the FDA for its Premarket Notification, 510(k) for Proxcelan Cesium-131 Brachytherapy Seeds. It would enable the company to preload Cesium-131 into flexible braided
Light Sciences Oncology (LSO) has reported the first patient dosing in a phase 2 clinical trial of its targeted drug treatment, Aptocine (talaporfin sodium), in benign prostatic hyperplasia
Orexo has confirmed that Meda has initiated the launch of the drug Edluar in the US. The launch follows the US Food and Drug Administration’s approval in March
Abbott has signed a partnership with Velcera to market the first canine pain management product, delivered in a transmucosal mist form. Currently in clinical trials, the product combines
Geron has announced that its IND (Investigational New Drug application) for GRNOPC1 has been placed on clinical hold by FDA, pending the agency’s review of new nonclinical animal
Strategic Diagnostics (SDI) has bagged US Patent No. 7521201 B2 for using bacteriophages in microbiological assay tests and processes. The invention is a rapid bacterial detection method that
Biogaia in its interim report has reported an increase in net sales by 65% or SEK 23.8m to SEK 60.2m for the second quarter ended June 30,2009, compared